NantHealth, Inc. (NASDAQ:NH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07Submission of Matters to a Vote of Security Holders.
We held our 2017 annual meeting of stockholders on June13, 2017
(the Annual Meeting). Of the 121,626,567 shares of our common
stock outstanding as of the record date of April17, 2017,
96,367,538 shares of common stock were represented at the Annual
Meeting, either in person or by proxy, constituting approximately
79.2% of the outstanding shares of common stock. The matters
voted on at the Annual Meeting and the votes cast with respect to
each such matter are set forth below:
| 1. |
Election of Directors. Each of the following nominees was elected to serve as a director, to hold office until our 2018 annual meeting of stockholders and until his respective successor has been duly elected and qualified, or until such directors earlier death, resignation or removal, based on the following results of voting: |
|
Nominee |
Votes For | VotesWithheld | BrokerNon-Votes | |||||||||
|
Patrick Soon-Shiong, M.D. |
90,998,883 | 1,049,465 | 4,319,190 | |||||||||
|
Michael S. Sitrick |
91,153,372 | 894,976 | 4,319,190 | |||||||||
|
Kirk K. Calhoun |
91,186,536 | 861,812 | 4,319,190 | |||||||||
|
Mark Burnett |
91,182,436 | 865,912 | 4,319,190 | |||||||||
|
Michael Blaszyk |
91,182,836 | 865,512 | 4,319,190 |
| 2. |
Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst Young LLP as our independent registered public accounting firm for the fiscal year ending December31,2017 was ratified based on the following results of the voting: |
| Votes For | VotesAgainst | Abstentions | BrokerNon-Votes | |||||||||||
| 96,331,082 | 34,743 | 1,713 |
About NantHealth, Inc. (NASDAQ:NH)
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.